May bone-targeted radionuclide therapy overcome PRRT-refractory osseous disease in NET? A pilot report on (188)Re-HEDP treatment in progressive bone metastases after (177)Lu-octreotate.
about
May bone-targeted radionuclide therapy overcome PRRT-refractory osseous disease in NET? A pilot report on (188)Re-HEDP treatment in progressive bone metastases after (177)Lu-octreotate.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 15 December 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
May bone-targeted radionuclide ...... ases after (177)Lu-octreotate.
@en
May bone-targeted radionuclide ...... ease in NET? A pilot report on
@nl
type
label
May bone-targeted radionuclide ...... ases after (177)Lu-octreotate.
@en
May bone-targeted radionuclide ...... ease in NET? A pilot report on
@nl
prefLabel
May bone-targeted radionuclide ...... ases after (177)Lu-octreotate.
@en
May bone-targeted radionuclide ...... ease in NET? A pilot report on
@nl
P2093
P2860
P1476
May bone-targeted radionuclide ...... ases after (177)Lu-octreotate.
@en
P2093
Abdullah Al-Zreiqat
Amir Sabet
Feras Khalaf
Hans-Jürgen Biersack
Samer Ezziddin
Soha Mahjoob
P2860
P577
2013-12-15T00:00:00Z